Alma Therapeutics

Company Overview

Snapshot

Founded in February 2017 by Oz Cabiri, Alma Therapeutics operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on advancing its drug delivery platform. In February 2026, Alma announced a key collaboration with Universkin to introduce an FDA-listed daily mineral serum SPF 50, marking a significant product development and market entry milestone.

Business overview

Alma Therapeutics is a Health Tech & Life Sciences company developing a novel drug delivery platform, the Mobius Capsule, for the oral administration of complex and biologic molecules. This technology utilizes a microneedle-array approach to enable the oral delivery of therapeutic proteins, peptides, and antibodies that typically require injections due to poor oral bioavailability. The company aims to provide a needle-free alternative to injectable drugs, enhancing the quality of life for patients requiring chronic administration of such medications. Alma Therapeutics operates in the pharmaceutical and drug delivery sectors, targeting global markets with its B2B2C business model.

Strategic signal

In February 2026, Alma, a global leader in energy-based medical and aesthetic technologies, announced a key collaboration with dermatological science brand Universkin to introduce an FDA-listed daily mineral serum SPF 50. This partnership signals Alma's strategic expansion beyond its core drug delivery platform into the broader medical and aesthetic technologies market, leveraging its expertise in advanced delivery systems for new product categories. For investors, this indicates a potential diversification of revenue streams and a validation of Alma's technological capabilities in a competitive market.

Company Intelligence Q&A

What is Alma Therapeutics' primary focus?

Alma Therapeutics specializes in developing advanced drug delivery systems, specifically a capsule for the oral delivery of complex and biologic molecules like peptides, proteins, and antibodies.

What is the Mobius Capsule?

The Mobius Capsule is Alma Therapeutics' proprietary drug delivery platform that employs a microneedle-array approach to enable the oral administration of therapeutic proteins and peptides, which typically have poor oral bioavailability and require injections.

When was Alma Therapeutics founded?

Alma Therapeutics was founded in February 2017.

What significant product development did Alma Therapeutics announce in February 2026?

In February 2026, Alma Therapeutics, in collaboration with Universkin, introduced an FDA-listed daily mineral serum SPF 50, marking a new era in post-procedure skincare.

What leadership change occurred at Alma Therapeutics in December 2025?

In December 2025, Alma announced a leadership transition where Lior Dayan was appointed Chairman of Sisram Medical, following eight years of successful leadership as CEO of Alma.